Great-West Lifeco Inc
TSX:GWO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
38.84
50.79
|
Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Thank you for standing by. This is the conference operator. Welcome to the Great-West Lifeco First Quarter 2020 Results Conference Call. [Operator Instructions] The conference is being recorded. [Operator Instructions] I would now like to turn the conference over to Mr. Paul Mahon, President and CEO of Great-West Lifeco. Please go ahead.
Thanks, Ariel. Good afternoon and welcome to Great-West Lifeco's First Quarter 2020 Conference Call. I hope this call finds you and all of your families safe and well during these unprecedented times. Before we get started, I want to take a moment to acknowledge and thank all of the front-line workers around the world who put themselves at risk as we all do our part by physically distancing. We're truly grateful for your courage and commitment in helping us get through this crisis. With me on the call today is Garry MacNicholas, Executive Vice President and Chief Financial Officer. Garry and I will deliver today's formal presentation. And also joining on the call are David Harney, President and Chief Operating Officer, Europe; Arshil Jamal, President and Group Head, Strategy, Investment, Reinsurance and Corporate Development; Jeff Macoun, President and Chief Operating Officer, Canada; Ed Murphy, President and Chief Executive Officer, Empower Retirement; and Bob Reynolds, President and Chief Executive Officer of Putnam Investments. Before we start, I'll draw your attention to the cautionary notes regarding forward-looking information and non-IFRS financial measures on Slide 2. These cautionary notes will apply to today's discussion as well as to the presentation material. Our presentation will follow a slightly different format this quarter, where I will start by addressing the company's response and positioning as it relates to the COVID-19 pandemic. I will discuss the impact that pandemic has had on the company to-date, the actions we're taking in response and our expectations for the near term. Garry will then take you through a more detailed financial review. And following our prepared remarks, we'll open the line to questions. So I'll ask you to turn to Slide 4. From the onset of the COVID-19 pandemic, we made safeguarding the health and well-being of our employees our #1 priority. In mid-March, we enacted our business continuity plans across the organization. And today, 98% of our employees around the globe are working remotely. I would like to thank our 24,000 employees across Canada, the U.S. and Europe for the resiliency and commitment during this period of extraordinary change. I could not be prouder of how we as a company have embraced and adapted to these new ways of working. We've maintained business operations by leveraging the investments we've made in technology, and we've quickly adopted new digital ways of working. This includes allowing e-signatures on virtual claims and increasingly using tools like SimpleProtect, our online life insurance application. We're also helping our customers weather financial and personal challenges. We've extended grace periods for life insurance premium payments, and we're providing mortgage payment deferrals for those who've lost their income because of the crisis. We're also helping our Canadian customers manage their physical and mental health by connecting them with health-care professionals via Dialogue, a virtual health-care app we have invested in. On the group side, we've reduced health insurance premiums for employer-sponsored plans, supporting over 26,000 small- and medium-sized businesses in Canada. We're also allowing plan sponsors to extend disability coverage and other benefits for temporarily laid-off workers. In the U.S., Empower Retirement is waiving fees on all new retirement plan loans and hardship withdrawals, and Irish Life is providing health insurance customers with rebates following the temporary nationalization of private hospitals in Ireland. In addition to our greater use of digital tools, we're adapting our processes to align with the realities of physical distancing. We have temporarily relaxed some of our medical underwriting requirements at Canada Life in Canada, allowing us to fulfill a wider range of customer needs. In the U.K., where traditional approaches to property valuations are no longer feasible, we're transitioning to remote valuations for equity release mortgages. Across the organization, we've extended call center hours and increased call center capacity to accommodate higher call volumes. We've also been partnering with governments, regulators and the industry to support the economy. In line with OSFI guidelines, we've suspended share buybacks and have no plans to increase dividends for the time being. The premium rebates announced by Canada Life are an extension of our participation in the Canadian Business Resilience Network, and we'll continue to work with the federal government to champion relief measures for Canadian businesses. We've donated over $2 million to relief efforts in communities across Canada, the U.S., the U.K. and Ireland. These contributions will help support food banks, front-line workers and those most vulnerable in these challenging times. These types of responses from governments and businesses, along with the amazing commitment of the front-line workers, have helped to create some stability. We recognize that there's still much uncertainty ahead as countries and economies gradually reopen, but it will take discipline, adaptability and creativity to manage the way forward. Fortunately, our company has entered this period in a strong financial position. Our balance sheet, the strength of which was borne out during the financial crisis 11 years ago, is even more resilient now with lessons learned from that crisis. In the years since, we've invested heavily in our risk management capabilities and taken action to derisk our investment portfolios. These actions stand us in good stead to navigate the current environment. We entered 2020 with a strong capital position. Our LICAT ratio at the end of the first quarter was 133%, well above our internal target range of 110% to 120%. We have a diversified and resilient business model that is balanced across geographies, products and risk types. Our investment portfolio is conservative and of high quality, and our asset/liability matching philosophy largely insulates us from interest rate movements. Beyond this, our disciplined and sophisticated risk management capability has supported an important scenario-based analysis we've done related to this crisis. Discipline extends to every aspect of how we manage our business, from pricing to reserving to how we approach M&A. We're also disciplined when it comes to expense management, and we will continue to look for opportunities to reduce costs with continuing to invest in important initiatives. Please turn to Slide 5. While the crisis only took hold in mid-March, the swift and severe downturn in markets had a significant impact on our first quarter results, reducing net earnings by approximately $300 million. As a reminder, we've adopted a new non-IFRS earnings measure called base earnings to help describe our results. Base earnings were $0.59 per share for the first quarter, up 2% year-over-year. While the year started off strongly in a number of areas, the onset of COVID-19 negatively impacted base earnings by $0.07 per share. Approximately half of the impact was due to seed capital losses at Putnam and the remainder from impacts on fee income in Canada, the U.S. and Europe. Net earnings of $0.37 per share were down 45% year-over-year and included the negative impact of actuarial assumption changes and management actions and other market-related impacts. Garry will take you through details of the earnings in his formal comments. I will now comment on Slides 6 and 7. These slides will give you more color on what we are seeing in each of our businesses. We've also provided details on our near-term actions and expectations moving forward, recognizing there is still much uncertainty regarding how this pandemic and its economic impacts will play out. Across Lifeco, fee income was negatively affected by the market declines, but the impact was relatively modest given the timing later in the quarter. Expectations for fee income going forward will depend on future market movements. We did not see any material impacts from mortality across the businesses. We would expect limited financial impact from increased mortality, given the age demographic and diversification of our life and annuity liabilities. In Canada, we've seen slow -- lower health and dental claims as clinics have closed, and we've provided premium reductions to reflect this reduced access to services. We've also seen a modest increase in disability claims. We expect health and dental claims to gradually return to normal levels, and we'll closely monitor disability claims experience. Beyond adjusting price as access increases, we will leverage our prescription drug and disability management services to help employers navigate this complexity. Increasing unemployment could lead to impacts on our group businesses in Canada, Ireland and also Empower. While there is potential for an increase in plan terminations, government programs and the flexibility we have introduced has limited any significant impacts to-date. We've seen a slowdown in the group sales cycle across geographies as some businesses remain in lockdown. However, to-date, we've also seen this offset by lower-than-expected plan terminations. At Empower, we could also see declines in assets and fees as plan participants under financial stress borrow or withdraw from their retirement savings under the CARES Act. To-date, we have seen limited withdrawals from plan participants, and they've stayed invested. Of note, we've seen increased interest in digitally delivered managed account advisory and financial wellness offerings. One great aspect of the Empower platform is that it focuses the participant on their future monthly retirement income rather than their current account value. This creates less sensitivity to market movements and limits reactive selling. We've also expanded the availability of one-on-one counseling sessions at Empower to meet the needs of retirement investors seeking advice. At Putnam, market volatility in the first quarter led to elevated redemptions, in particular in the short-duration and the ultrashort-duration lower fee fixed income products and as well as seed capital losses. In April, as markets stabilized and improved, seed capital losses have partly recovered, and Putnam has moved to positive net cash flows overall. Putnam continues to focus on strong investment performance with 28 funds having Morningstar 4- or 5-star performance. In the U.K., we've seen a slowdown in individual and bulk annuity sales as market instability and lower asset values keep people and pension funds on the sidelines. We expect this is temporary, and we expect to see a return to more normal sales levels as markets stabilize. As noted, there's been a slowdown in equity release mortgage originations, but our transition to remote valuations could help on this front. Similar to Canada, rising unemployment and lockdowns could impact group risk sales in the U.K. and Ireland, but we expect this will be offset by lower plan terminations. At Irish Life Health, premiums are down because of the rebates, but these are essentially offset by lower claims due to the temporary nationalization of private hospitals in Ireland. Turning to our newest reporting segment, Capital and Risk Solutions. We started the year with a strong sales pipeline, which remains intact. We expect more demand for life capital solutions in the U.S. and Europe. While demand is currently strong for European longevity, we do expect it to slow later in the year and early next year. Pricing and demand are solid for P&C reinsurance, and we will continue to participate in that market in line with our risk appetite. Please turn to Slide 8 for a deeper dive on our invested assets portfolio and the actions we've taken to derisk the portfolio since the financial crisis. Today, the portfolio is diversified, high quality and well positioned for the current economic challenges. It's made up of 69% bonds, of which 99% are investment grade. Since the financial crisis, we have reduced below-investment-grade exposure to $643 million or 0.5% of the bond portfolio, and our European subordinated bank exposure is 1/4 of what it was in 2009. Turning to our U.K. retail property-related portfolio. I would note the following high-level points. There have been no new purchases of direct nonfood retail property since 2010. We have limited new commercial mortgage exposure, and all postcrisis loans are at low LTVs with strong covenant protection. And we have taken opportunities to reduce direct retail property assets and precrisis commercial loans. More specifically, our U.K. retail property-related portfolio is $2.4 billion, a little over 1% of invested assets. Mortgages have an average LTV of 51%. And the majority of mortgage and investment property exposure, a little over 70%, is grocery, warehouse and distribution centers. These are properties which are more resilient both to online shopping trends as well as economic downturns. Across Lifeco, the negative earnings impact from corporate bond downgrades in the quarter was $19 million. There was a $32 million after-tax negative impact related to U.K. property-related investment losses. We expect to see impacts of a similar magnitude for the next few quarters as companies remain challenged and the downgrade cycle continues. While we remain cautious, we expect the impact of downgrades and defaults in our corporate bond portfolio, resulting from the current credit downturn, to be manageable in the context of our total invested assets. Please turn to Slide 9 for a summary of other results in the quarter. In Canada, strong individual wealth sales were driven by our new segregated fund shelf, and higher individual insurance sales were driven in part by a new par product we launched on January 1. While COVID-19 has impacted adviser customer interaction, tools like our SimpleProtect app have helped sustain momentum. In the U.S., Empower recorded sales of $25 billion, driven by higher mid- and small-market plan sales. The year-over-year decline reflects a large-plan sale with 200,000 participants that we booked in Q1 2019. And while the sales cycle has slowed, Empower's pipeline remained strong. At Putnam, gross sales were up, but net outflows increased significantly with steep decline in market towards the end of the quarter. In Europe, sales were up 47% over Q4 2019 but down 14% compared to Q1 last year. Lower annuities were partially offset by higher equity release mortgage sales in the U.K. Sales were lower in Ireland compared to Q1 2019, which included a large fund mandate at ILIM, and there was higher pension sales in Germany. Turning to Slide 10. Lifeco fees were level year-over-year, excluding Q1 2019 fees related to the sold U.S. Individual Markets business. As equity market declines occurred later in the quarter, fees reflected higher average equity markets and assets when compared to the first quarter last year. Excluding fees related to the sold U.S. individual markets business last year, fees in the U.S. were up 8%, reflecting participant growth at Empower and improved performance fees at Putnam. Fees in Europe were down due to the Scottish Friendly transaction in the U.K. and other income in Ireland. And turning to Slide 11, dealing with expenses. Lifeco's operating expenses were up 3% year-over-year, reflecting continued expense discipline company-wide and strong business growth in Capital and Risk Solutions. With that, I will now turn the call over to Garry. Garry?
Thank you, Paul. Starting with Slide 13. Base EPS was $0.59, up 2% year-over-year. This includes the combined impact of the sale of the U.S. individual markets business, which had contributed $33 million to base earnings in Q1 last year and the substantial issuer bid, which offset the dilution through share buybacks. In Canada, base earnings improved 6% from last year with strong trading gains being partially offset by higher disability claims. In the U.S., we saw good underlying business growth in Empower with participant growth at 6%. But this was offset by seed capital losses of $30 million in Putnam, driven by market declines. As noted, the prior year included $33 million from the individual markets business. In Europe, base earnings were down 19% due to lower new business gains and a swing in the impact of credit downgrades, which were positive in Q1 last year and negative this quarter. The Capital and Risk Solutions segment saw a very strong year-over-year business growth, particularly in longevity reinsurance solutions. Base earnings were up 60%, which also reflects new business strain last year that did not repeat this quarter. Overall, before COVID-19 emerged, base earnings had been on track for a strong year-over-year growth, driven by buoyant markets coming into 2020 and good underlying performance with growth in all segments, particularly reinsurance and Empower. By quarter end, market turmoil caused by COVID had negatively impacted both base and net earnings, as highlighted in more detail on the next slide. So turning to Slide 14. The upper table on this slide is a reconciliation of base to net earnings. It is important to note that not all the items excluded were COVID-19-related. For example, the negative $52 million of actuarial assumption changes and management actions included negative $98 million related to COVID and a positive $46 million for other actuarial reviews. It is also important to note that the market-related impacts include $35 million of a U.K. tax benefit as a result of the market declines, which led to a lower overall tax rate but did not affect the tax rate on the base earnings. The lower table sets out the impact of COVID-19 on both base and net earnings. The impact on base earnings was a negative $65 million compared to expectations, largely reflecting the fallen markets in March with fee income impacted by $31 million and seed capital by $34 million. The fee income variance is a run-rate impact with the go-forward outcome clearly dependent on the trajectory of markets and average levels over time. The seed capital loss is a mark-to-market impact, an unrealized gain/loss position that gets evaluated at a point in time. For example, at April month end, seed capital had recovered some 40% of the reported loss as markets rebounded. For excluded items, the actuarial assumption changes relate to updated equity return assumptions following the market decline in the quarter. The market-related impacts included remeasuring segregated fund liabilities from the lower starting point of the quarter end market levels. It also includes the impact of hedge ineffectiveness and the U.K. tax gain noted earlier. Please turn to Slide 15. This table shows the segment and total Lifeco net earnings results from a source of earnings perspective. And as a reminder, the SoE categories above the line are shown pretax. Excluding U.S. individual markets, expected profit was up 10% year-over-year, reflecting market gains during 2019 and strong business growth at reinsurance Empower, noted earlier. New business strain of $86 million pretax in quarter was a little higher than Q1 '19, largely in Canada individual insurance business due to declines in interest rates that have not yet been fully factored into repricing. Experience gains and losses reduced earnings by $195 million in quarter, which includes $237 million related to COVID-19 and a positive $42 million from other experience. Management actions and changes in assumptions reduced earnings by $81 million this quarter. Updates to equity return assumptions reduced pretax earnings by $134 million. Other changes and assumptions contributed to positive $53 million. Again, these are pretax. Earnings on surplus of $4 million in quarter reflected $37 million pretax losses on seed capital, primarily at Putnam, due to the COVID-19 market-related impacts. Seed capital gains had been a positive quarter -- a positive contributor both in prior quarter and in the prior year. The effective tax rate on shareholder earnings was marginally negative this quarter as net earnings benefited from approximately $35 million of U.K. tax recoveries following the market decline. Note this benefit is excluded from base earnings. The effective tax rate on base earnings was 9%, which reflects the jurisdictional mix of income this quarter. Please turn to Slide 16. These tables expand on the experience results and changes in assumptions to highlight various items in the quarter. Again, these are on a pretax basis. Starting with experience results. Yield enhancement continued to contribute positively. While there were some limited benefit from the widening spreads in March, this could be an opportunity going forward. The market-related impact on liabilities includes the impact on the value of segregated fund and variable annuity guarantees, including legacy blocks in Irish Life and reinsurance, largely a result of remeasuring the liabilities using the market level and interest rates at the end of the quarter. Experience losses also include some hedge ineffectiveness on our GMWB products given the extreme market volatility. Also included is the impact of the decline in market value of certain U.K. properties, which support insurance contract liabilities, as Paul noted earlier. We observed mortality gains on our annuity and life books across Canada, U.K. and Ireland this quarter, although we have not yet seen the expected increases in mortality, particularly at the older ages, as a result of COVID-19. And the credit-related impacts arose from bond downgrades in the quarter, mainly in the U.K. portfolio. Please turn to Slide 17. Our book value per share was $22.34. And while the substantial issuer bid impacts the year-over-year comparison, you can see good sequential growth primarily due to currency translation. Lifeco cash rose to $900 million with additional dividends from Canada Life in period. This, in turn, reduced the Canada Life LICAT ratio modestly since the Lifeco cash balance is not included in LICAT. Business growth, particularly in reinsurance, added to requirements, which also tends to lower the ratio. Given the LICAT design, the market impacts were minimal, and we remain well positioned from a capital standpoint. That concludes my formal remarks, Paul. Back to you. Back to you, Paul.
Thanks. I was being very eloquent there on mute. Apologies to everyone on the call. I'd ask you to turn to Slide 18, where I'll conclude the formal presentation by emphasizing our focus on protecting, adapting and growing our business. First, we turn to the safety and securities of our employees, advisers and customers, which remains paramount. As jurisdictions open up, we will be cautious as our business model is working very well the way it is today. Second, we've seen an acceleration in adoption of digital platforms, perhaps 2 or 3 years of expected progress in 1 month. We will invest further both in our existing businesses and through acquisitions to advance this and improve customer and business outcomes. Third, we recognize that more than ever, capital is critically important to our stability, adaptability and growth. We will actively and prudently manage our capital with a balanced focus on stability and growth. And finally, despite the challenges presented by COVID-19, we remain proactively focused on growth. We view this as a time to identify and act on opportunities that will drive long-term growth and shareholder value. So before closing, let me reiterate my thanks to all of our stakeholders for doing their part to collectively respond to and overcome this crisis. With that, I'm going to ask the operator to open the line for questions. Given our team is spread across multiple locations, I would ask that analysts, please direct all questions to me, and I will steer them to the appropriate respondent. And we should just recognize there may be a pause as people mute and unmute, and I think I'm a perfect example of that just a couple of minutes ago. So with that, operator, could we now please open the line?
[Operator Instructions] Our first question comes from Gabriel Dechaine of National Bank Financial.
I've got one question about your European business and specifically about the regulators and some of the restrictions that are being implemented on dividend payments to shareholders. Just wondering how you're thinking about that in relation to your European sub dividend-ing earnings to the Canadian whole company and how that affects the Canadian dividend to Canadian shareholders. It looks like the U.K., more flexibility, Germany as well, but Ireland might be a bit of a hitch.
Yes. Gabriel, I'll take that one. I'll start off by just outlining that we do recognize the importance of dividends to our shareholders and remind listeners that we have a long track record of maintaining dividends, even including through the last financial crisis. And of course, we can't predict the future. But as things stand, we actually expect to be able to continue paying dividends at current levels. And we'll be monitoring the situation. And to your point, we operate in a number of jurisdictions, and local regulators can, from time to time, delay dividends up to our holding company. But the reality is, we've actually managed through those issues in the past. And today, our capital position and liquidity at Great-West Lifeco remains strong. If I go to jurisdictions, Canada, there's been direction to not have any increases or buybacks. In the U.K., there's just been guidance to insurers to use prudence and take into account stressed scenarios. And Ireland, yes, there has been a recommendation or a direction to defer until we fully assess risk. And I would say none of this is out of the norm. So we feel quite comfortable right now.
Can you remind me of previous instances when this was a problem or an issue or whatever?
This would have just been when we were going through various restructuring or acquisitions and the like. And it would have been nothing -- it wouldn't have been a systemic issue. It would have just been as we were managing our affairs.
Our next question comes from Tom MacKinnon of BMO Capital.
A couple questions. First is just why the move to base here? I mean, traditionally, you just really focused on reported numbers. And why are you moving to this base earnings metric?
And did you have a second question, Tom? Or was that the single question?
The -- yes, sure, that's a good point. The second question is really just given lockdown and everything else, just wondering how sales are progressing. I think you did mention your positive net flows in April at Putnam but just seeing how sales are going kind of globally with you guys in April and both on the individual side and the group side as well.
Okay. Well, let's -- we'll deal with those in the order in which you asked them, Tom. And I'll defer to Garry in a moment on -- in terms of base earnings. We essentially believe that we can better describe our earnings and our movements by using this non-IFRS measure. I think it provides insight into the ongoing growth in our sort of core operating income as opposed to the movements on the balance sheet, and we think it's a good way to differentiate those 2. We also think it will serve us very well as we transition to IFRS 17. But I'm going to let Garry add a little more color on that, and then he can pass it back over to me to deal with the sales. And then I'm going to actually refer on to some of our other leaders to provide a little bit of insight on where sales are at in April. Garry, over to you.
Yes. Tom, I think you hit the 2 key points. One is we are aware that reading reports that a lot of people do adjust out and try to make adjustments for various factors. We've called them out in the past in the term of adjusted earnings for things like restructuring and some of these other items. So we already had an adjusted metric. And we found that formalizing the measures and making an effort to align it with some of the peers in the industry so that there's some level of consistency, and in preparation for IFRS 17, we just felt it was the right direction to go. And again, at the time we were bringing it in, IFRS 17 was 2 years away. And it seemed like the right time to be making this move to, again, regularize the adjustments and have them clearly defined and laid out in the MD&A. And then, as I say, for the market-related, that's -- a lot of that is where we see things going on the IFRS 17 side. So that's the background to it. I should add, Tom -- well, for the benefit of all, that this is in no way signals a change in our views on the importance of any of the aspects of it. We continue to manage our affairs the same way. This is a presentation to try and make it easier period-over-period to see the underlying growth in the business. We've had a history of positive contributions from some of the items that are now excluded, and we're still managing our balance sheet in the same fashion. So I wouldn't leap to any other conclusions in that. Just I want to reinforce it. It hasn't changed our view on our total earnings.
Thanks, Garry. Tom, on -- and the other thing I would say is that this is something we've been working on, as Garry pointed out, for about a year. We've been back-testing and looking at it and thinking about this, and our timing was interesting, given the fact that we -- COVID was upon us mid-March. But the reality is we decided it was still the right thing to proceed ahead. That's -- we had sort of developed all of our information around that. Turning to your question on sales. I'll just generally say that, while the whole issue of physical distancing creates -- requires a change in approaches in terms of the sales processes and the sales cycle, we've actually been actually quite pleased with what we've seen through April. And the reality is you can't kind of guess exactly what -- how the future will play out. We have seen pretty good resiliency in the whole sales process and sales as they've flown through. Maybe I'll ask each of the leaders in each of the regions, and I'll just call on you one at a time to provide a little bit of color on where you see sales at. I'm going to start with you first, Jeff Macoun, on Canadian sales in quarter -- in April.
Paul, thank you. And Tom, so let me expand on Paul's question. I'm quite pleased to say that our strong start in the quarter on individual life and wealth business has continued into April. As a matter of fact, in April, we saw an increase in April in '20 over '19. Now I will say that we do come into this with a relatively large pipeline. And I would suspect that we'll start to see that drop a bit in May and obviously beyond but a very strong April. I'd also say on the life side that, it's interesting, as Paul outlined. We've transitioned nicely to the digital world. And in the month of April, close to 70% of our transactions were done non-face-to-face using SimpleProtect, which Paul talked about earlier, so strong in April. I'm also pleased to say that the product enhancements we made on the wealth side in -- late in the year and into '20 that we saw positive flows in the month of April on our wealth side in our proprietary funds, third party and seg. So although gross sales were down, positive flows. On the group side, we have seen lower amounts of activity. Quotes are down about half, and that would be similar in the industry. I am pleased to say, though that terminations were very low in the month of April. So with lower quotes, you get lower terminations. And I would say that's the same for both the life and health and retirement side. Paul?
Thanks, Jeff. Maybe I'll ask Ed Murphy just to speak to what he's seeing at Empower.
Yes. Thank you, Paul. We had a very strong first quarter sales. April, sales were a little bit weaker, off about $1 billion versus prior year, but the pipeline remains very strong, over $600 billion. Our large/mega market had a strong first quarter and had a strong April. Where we've seen a little bit of softness is in the smaller end of the market, call it under 1,000-employee companies, but that's also where we have a pretty significant pipeline. So I would say that I'm pretty optimistic on the year. I think that the sales cycle has been extended, elongated a bit in light of COVID. But I'm encouraged with the pipeline and the activity that we're seeing in the marketplace.
Bob, is there any other color you'd like to provide on sales that you're seeing at Putnam? I mean, obviously, I made reference to positive flows and sales coming back. Any additional color on that?
No. The only thing I would say is having 28 4- and 5-star funds by Morningstar, performance is strong across the board. And the primary outflow in the first quarter was in one fund, the ultrashort-duration, where, at a point in March, rates really -- the spread of rates really ratcheted up due to liquidity issues. So it was driven by primarily one fund.
Thanks, Bob. And finally, David Harney, do you want to provide a little color on what you're seeing going on in Europe on the sales side?
Yes. Like as Tom suggested in his question, it does vary between retail and nonretail. In Germany, most of our sales are retail-related, but I think that country has been less impacted by the crisis than the U.K. or Ireland. So sales in Germany actually continued to be good and, year-to-date, are up on last year and ahead of targets. Within the U.K., we have less exposure to retail sales. The story in the U.K. has been lower bulk annuity -- well, low bulk annuity sales in the first quarter, but there are signs of activity now returning to the market there, and we would expect bulk annuity sales over the rest of 2020. And then within Ireland, I suppose our sales are split between retail and corporate. Corporate business sales have been very good in quarter 1 and in April also, and we are seeing a slowdown in retail sales. But overall, Ireland sales would still be up on last year. And then I suppose the cash created outside of all of that is our large institutional investment-only-type sales. And they're not really impacted by the crisis. But the winning of those mandates, that they're pretty lumpy and they just vary over time, anyway.
Yes. And I think we'll close maybe with that -- and I mean, we're taking a bit of a trip around the world. And then Arshil's business is actually virtual because it's in every continent. So Arshil, maybe you can comment on reinsurance, capital and risk Solutions and activity there?
Yes, Paul. Happy to give a little bit of color on the reinsurance side. We're having very active conversations with all of our existing clients, staying on top of the performance of our existing transactions. And then more importantly, the clients are very open to considering us not only on our traditional product ranges and on the P&C side but also, on the longevity side, we see a very strong pipeline and good conversations underway. And then on the structured capital solution side of the business, as people are feeling pressure or expecting to feel pressure on their businesses in the coming months, there are a lot of conversations underway. So again, I'd be very optimistic that any disruption will be very short term or whatever and, by the end of the year, that we'll be in a very good position from a sales perspective.
Thank you, Arshil. So Tom, we took a lot of time, and that's probably the longest answer you've ever had to a question, but it was a fairly broad one. I thought it was helpful that all call participants would get some insights into that.
Our next question comes from Paul Holden of CIBC.
So Paul, in your prepared remarks, you made some comments that you remain committed to capital deployment options. Wondering if the current situation alters the way you're looking at some of those options or maybe focuses you on certain priorities over others? And then maybe within that, you can comment around comfort around timing of completing, say, a large M&A deal.
Yes. So I may not get to the level of detail that you're hoping for there, but I'll give you some context. The way we look at a period like now where there's dislocation is that it is hard to -- it is always more difficult to price a transaction at a period like this where you have a lot of market volatility and instability. Are you pricing it off of market levels that start at middle -- beginning of March, end of March, what's happened today versus next week? But as markets stabilize, you can get some better comfort around the underlying value. And I think that's both a mindset for the buyer and the seller. You're trying to find the right value. I think the second I'd say is that dislocation actually creates some opportunity. We would characterize ourselves as having strong capital, and you've got to make sure that you're balancing your capital relative to the apparent risk today but also thinking about opportunity. And if I reflect back on our move on Irish Life, if you go back to -- as we were looking at it through the 2011/'12, end of '13 period, when we moved on it, one of the things that would characterize that move was that there was dislocation and some of the other people who might have been -- or organizations that might have been thinking that business chose to pull back. Our view is dislocation. If it's a good value property, it's one where it could create some opportunity. The other factor I would put into play is that I think we've always been thinking about making sure that our businesses have scale but also think about how do you enhance capabilities from a digital perspective. And as we're looking at transactions now and thinking about the uptake and leverage in digital capabilities, it's something that is top of mind as we're assessing opportunities and targets right now. Is it going to be something that's going to really enhance our business? Because I think a lot of this shift in behavior is not going to be short term in nature. I think a lot of it's going to be locked in, in terms of the ways of working or ways of selling or ways of advising into the future. So that would be another mindset we'd have. I would say that, from a geographic perspective, we continue to view the U.S., Empower in particular, as a place where there's going to be opportunities to both bolster scale and capability; Putnam, the right target, in terms of scaling assets there. And Europe, we will continue to have a focus there. But again, we will look at all of these things in the context of ensuring that we feel confident in the valuation, and we feel confident in our ability to execute in an environment that's going to be -- have a little bit more uncertainty. So that's the context I could provide on that.
Great. That's helpful. And second question from me is, if you can provide us some context for takeup on premium deferrals. I don't know if you can give it on an aggregate basis or maybe sort of on a segmented basis. So that's the first part of the question. The second kind of part of that question is, how does that -- how do premium deferrals flow through on an accounting basis in terms of SoE?
Okay. I'm going to actually let -- I think that's a 2-parter. Part of it is takeup. And when I think about premium deferrals, that's been predominantly a Canadian phenomena. I know that, within the Empower business, there's been allowing for people to not be charged loan fees. That is a -- not a material amount. It's -- takeup hasn't been high there, and it's not material. In the context of Canada, I think Jeff Macoun can provide a little bit of insight into whether premium deferrals has been -- what's the scale of it. And I don't think Jeff's going to provide you an exact dollar amount, but he can give you a sense of whether it's sort of meeting where our expectations were. And then secondarily, I think Garry could provide a little bit of color on the accounting treatment of that. And so I'm going to turn that over first to Jeff Macoun for a little bit of context on the premium deferral activity we've seen.
Thank you, Paul. So I think, as you know, and Paul called out in his comments, we did have premium credits, we'll call it, to the small- and medium-sized businesses, about 26,000 across Canada. That's the context of the scope where we put through a credit in the month of April. And we indicated we would be looking at that on a monthly basis. We will be moving forward again in the month of May, and we'll continue to monitor that month-by-month to see where we're at with regards to dental clinics and paramedical services, et cetera. So the takeup on that would be 100% of all the clients. And the feedback has been, as you might imagine, outstanding for the clients. So we do provide a credit on that, and the percentages vary by the benefit. So that'll continue on month-by-month until such time that we feel we're back in a position where everything is running smoothly. On the individual side, we haven't had significant takeup on the deferrals in terms of moving, call it, [indiscernible] base, I would say, it's been relatively small as a percentage of our overall block at this point. So those are the comments I would offer, Paul, at this point.
Yes. And Paul, the point I'd make on the premium deferrals that Jeff is referencing there is that was -- those were calculated, frankly, to offset the reduction in claims that we were seeing. So the actual impact that we'll see will be lower revenue and lower claims broadly offsetting one another. And from the standpoint of other deferrals, we really haven't been deferring premiums beyond that because this has allowed employers to keep their plans in place. And as we've previously outlined, we're not seeing a spike in terminations. We're actually seeing terminations that have come down. Garry, any comments on the accounting treatment of that? Or is it just sort of flow-through?
Yes. I'll just clarify 2 things. One is the -- to the extent we've had, I'll call them, premium reductions rather than deferrals, just to get the terminology, to the extent we had a premium reduction and we're on the anticipation of lower claims, then both those adjustments, the lower premiums, low claims, will go through experience gain/loss. And obviously, we're looking to set that out towards roughly balancing. And then on premium deferrals where we extend grace periods or something, that won't have an impact on earnings. I think to the extent, and sort of going to the next step in your question here, if eventually people can't pay and those lapses, that lapse experience, positive, negative, will show up in the policyholder behavior side. But the active premium deferral itself extending the grace periods doesn't have any earnings impact -- any material earnings impact.
Our next question comes from Doug Young of Desjardins Capital Markets.
Just I guess a few questions. The actuarial assumption change, the $98 million related to changes in economic assumptions, and I apologize if you covered this in your prepared remarks, but can you flesh that out as well? The $149 million that you kind of strip out, I think you said that, that also factors in the $35 million U.K. tax gain. So that's taken out of base earnings. I just wanted to clarify that. And then I have a follow-up -- one follow-up after that.
Okay. Garry, I'm going to let you take those 2.
Sure. I'll answer the first one. And as I was writing my answer down, I'll get [indiscernible] to just reiterate the second one in a moment. The first one, on the $98 million, that was the -- that's the equity growth returns that these are for equities that comes off -- that are backing our long-tail liabilities in Canada. So we take a certain portion of our long-tail nonparticipating liabilities, and we back those with equities. And we've adjusted the growth assumption on that. Typically, for small movements, you can assume that the markets rebound or, in the case of market, moves up, they come down again towards your central assumption. The market move was so large that we're bumped up against actuarial limits. And so we had to just lower our overall growth assumption to align with the standard. So that's what that really was. It's just the long-term equity growth assumption came down. And if you don't mind repeating the second one, that would be helpful.
Garry, just before -- I would just -- I would characterize -- the reality is it was following actuarial standards. And as always, we're going to approach these things with the appropriate level of conservatism because that is the reality of the way actuarial standards work. Garry -- Paul -- Doug, the second question, can you provide a little bit more color?
And just maybe if I could follow up on that one before we go on. Is this -- are you in -- like you mark-to-market the equities backing liabilities? Or do you use a corridor approach in -- and that's -- you're just kind of adjusting that corridor approach?
The idea is more of the latter. It's more of a smoothing approach. And we're just at the -- there's no further room to smooth those. So we took it in, and it effectively works a bit like a mark-to-market on the amount that was outside that corridor smoothing. And the -- I think where you may be going to Congress with that is it would tend to reverse as markets improve or, obviously, they could go the other way if markets got worse. But it will move around a bit more, and we would call it -- sorry, go ahead.
No. I was just going to say, how much -- like how much buffer do you have before you -- like in that quarter, if you're willing to tell us, like how much do you typically have before you have to make a change to your reserves backing long-term liabilities?
Yes. It's -- I don't have a -- like a dollar quantification for it. It's more of a complex smoothing mechanism. So I think we are closer to the limit to that. That's why a lot of the change went through the markets. And then, again, as markets improve, a lot of it comes back. But it is more complicated than just a dollar figure corridor. [indiscernible] smoothing mechanism.
Doug, your second question?
Yes. Just on the $149 million, does that -- I think you said it factors in the $35 million tax gain, like that's embedded in that. So you are backing that out. Is that correct?
Correct. It would have been $184 million, and then the tax benefit was a positive. So it's a $149 million.
Okay. And then lastly, the U.S., I think you said in your presentation, the U.S. expense growth, if you exclude individual markets last year, it was about 10%. I didn't see any indication what was happening there. So I'm just looking for a little more detail as to what drove that.
I think the main driver of the growth would have been just the growth in the business at Empower. That's -- I think the participant growth alone was up to 6%. I'm not sure off the top of my head whether currency had an impact, but that was -- a lot of it was due to growth in business and, again, that Putnam would have grown business-wise. I beg your pardon?
No, I was just saying fees were up 11%.
Yes. On the fees, it would have gone up commensurately with it. So that's where it was going. You have growth on both sides.
[Operator Instructions] Our next question comes from Mario Mendonca of TD Securities.
Could you just clarify that $134 million that Doug was just referring to, it is possible then, given how sharply markets have rallied since the end of the quarter, that a portion of that could come back in Q2. Is that fair?
That is correct.
And then specifically now on the $215 million, the market-related impact on liabilities that goes through experience gains and losses. Has the company provided any sensitivity that we could use to gauge that, the potential gains and losses going forward they experience gains and losses now?
Garry?
Yes. And in fact, we've expanded our disclosures in this last -- trying to -- just to add both the 10% and the 20% we found that with the potential market swings, perhaps a 10% plus or minus was not enough. So we've added a 20%. So we do have the impacts that can arise from these changes. In terms of -- so some of them would be -- some of the elements such as hedge ineffectiveness, those would not -- they would not be an incentive. That's an in-period extreme market volatility. So you wouldn't see that. It's more just the actual liability changes from the movements in markets. And that's really the way you do your integrity funds, using the current market levels at the start point to run all your various liability models.
Okay. I'll find that. And just one final quick one. I think in your opening comments, I think it might have been you, Garry or maybe Paul, referred to the strain being higher because you hadn't priced in the reduction in interest rates. Is the suggestion then that you have the flexibility to raise pricing and we could see strain come down meaningfully in the short term?
I think there's 2 issues to that. If we raise pricing, for sure, you would see the strain on new sales come down. So -- and you always have the flexibility to raise price. And then the question is, where are we at relative to where we want to be from a pricing perspective? And I'd say right now, we're taking a close look at that. We took some pricing action in the first quarter on certain Canadian products. I think Jeff could provide you with some context on that. And then the key question is, what do we do on pricing now relative to our life and individual disability products that where we would have seen that strain? Jeff, any comment on pricing actions taken? And obviously, you're not going to provide guidance on specific pricing action, but the other way you're thinking about it.
Yes. Thank you, Paul. And Mario, we did get ahead of this on the UL side a number of months back. So you'll see that start to flow through. And on the term insurance side, of course, we have plans to get after that as well. But I would say the UL is the main area.
Yes. And what you see in any given period is products that would have been underwritten or applied under a pricing basis that was a couple of months ago. And to the extent that we were now starting to -- the sales that are flowing through are on a higher pricing basis, you'll probably -- you'll see some less strain coming through.
Our next question comes from Darko Mihelic of RBC Capital Markets.
I just wanted to go back to the dividend question for a second and just -- whereas I understand you're committed to it. I think what might help also is just the level of importance of Ireland and, say, the U.K. in terms of cash that's pulled up back to the Lifeco -- the holdco, I should say. And any other levers you could pull that would give investors comfort that you could bridge a short-term moment here in time by pulling on other cash levers. I understand the $900 million at the holdco. I'm just wondering how much else you could pull from others [ with this ] and/or other cash resources you could use to bridge a period of time where regulators may restrict you from pulling cash out of Europe.
I'll start, and then I'm going to turn that one to Garry. I'll start out by saying that the overall disclosure we provided was that, given the current conditions and looking at the current environment, we are comfortable with our ability to continue on with dividends at their current levels for the foreseeable future. So that is the comment we've made. In the context of the various jurisdictions, as I outlined before, Ireland is a place where they've said until things stabilize a bit, but the reality is we do have excess capital in various parts of our businesses. The other comment I'd make is that when we report on our overall European business, there's also elements of our business where we're reinsuring and using our internal reinsurance capabilities. So not all of our earnings that would come out of Europe are going to be fully limited by any actions taken by a regulator. But I think I'll let Garry start off with that, and Arshil may want to provide a little bit of context as well. Garry? Garry, I think you're on mute.
I'm sorry. I am on mute. I was just -- which aspect in terms of the geographic split of the earnings?
Yes, or just our comfort in terms of having access to enough liquidity for an interim period, if there was any restriction.
Well, certainly, first of all, we are starting to say with the Lifeco cash up at $900 million, so there's a fair bit there to start. And then our overall capital ratios at -- the LICAT ratio, well above our target. So again, there is room there within the European segment. That's just one segment. We've got the reinsurance, which is by and large outside of the European jurisdictions. There is a subsidiary there, but most of reinsurance is outside of Europe. And then the other thing we do, we do have internal reinsurance arrangements for some of our European business. So that's actually reinsured outside of Solvency II for capital management purposes. That does allow any profits on that business to flow up, again, not through Europe as well. So those are just some of the elements.
Okay. And I guess the question is, there's $900 million of cash, which is substantial and certainly pay -- the question, I guess, is what is the accessibility? Like how much more cash could you quickly access over the course of the next year or so should there be? Because one of the things that we worry about is if one jurisdiction prevents you from pulling cash out, others could quickly follow suit because they don't want to be rated either, right? So the concern would be that, eventually, what we see -- and perhaps some jurisdictions that actually ask you to downstream capital. So what is the capability of you raising cash rather quickly here over the course of the next year to make sure that the dividend, both pref and common, are taken care of?
Yes. Well, certainly, we do have untapped leverage capacity at the moment. We're a fair bit under the ratio. So that's -- I would -- everyone do their own estimates, but probably $2 billion, $2.5 billion of capacity there. So we would -- and I think I would not be unfair to say we have good access to the Canadian market, and we have tapped both the U.S. market and European markets in the past in terms of debt raising. So I think we've got flexibility in terms of which markets, and I think we would have good access to markets. And we have leverage room at our current ratings.
Yes. The other point I'd make, Darko, is that we haven't had to -- We haven't had to inject any capital into any of our subsidiaries. And so I'd point out, we have very, very strong RBC ratios in the U.S. So that gives you a sense of the capital strength and resiliency there. We are above our Solvency II target ranges in our European operations. So again, there's strength there. So we're not short on having overall capacity. The core issue is, do we have the flexibility? And what we're saying is that as we look at our situation, we believe we have enough flexibility in the system.
This concludes the question-and-answer session. I would like to turn the conference back over to Mr. Mahon for any closing remarks.
Thank you very much, Ariel. I'd just like to close and say, I do want to thank everyone. I realize this is a -- this has been an exceptional quarter end for our organization. I'm sure it's an exceptional quarter end for all of you in the work that you do. And I know there's been lots of information coming from us, coming at you. I appreciate your thoughtful questions. And I will say that we totally look forward to hopefully a more stable end of Q2. And in the meantime, please take care of yourselves and your family and your loved ones. Thanks very much.
This concludes today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.